Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2021, 46(1): 43
ISSN 0377-8282
Copyright 2021 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.1.3220744
What's in the pipeline for hidradenitis suppurativa? Emerging and novel therapeutics
Frew, J.W., Krueger, J.G.
Hidradenitis suppurativa (HS) is a complex inflammatory disease in need of novel therapeutic options. HS treatment is always challenging and requires a medical and surgical approach together with multidisciplinary evaluation. Multiple monoclonal antibody therapies (including interleukin IL-17, IL-23 and IL-1 inhibitors) are currently in clinical trials, with a number of these therapies identified from their use in psoriasis. However, it should be noted that while the pathogenesis of HS is incompletely defined it demonstrates a number of unique characteristics which do not overlap with psoriasis and may require unique approaches to therapy. This review aims to cover the therapeutic agents currently in clinical trials for HS as well as those which based upon our current understanding of HS pathogenesis may be candidates for future proof-of-concept studies and clinical investigation (including IL-36, IL-6R, IRAK-4 and BTK inhibitors). Additionally, the role of assessing clinical response in clinical trials is discussed given the known issues with outcome measures, placebo response rates and the natural variability of untreated disease.

Full Text: PDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences